论文部分内容阅读
目的:探讨米力农治疗小儿先天性心脏病并发急性心力衰竭的疗效及安全性。方法:选取2010年1月至2012年12月在我院就诊的先天性心脏病合并急性心力衰竭的患儿64例作为观察组,年龄3个月～2岁,平均8个月,经心脏彩超检查诊断为先天性心脏病,在常规洋地黄强心、呋塞米利尿以及卡托普利扩血管治疗基础上,予以米力农治疗;以同时期未予米力农治疗而只进行常规治疗的先天性心脏病合并急性心力衰竭的患儿53例作为对照组。观察治疗前后患儿心功能改善情况以及心脏彩超相关数据的改变情况。结果:观察组显效率64.1%,明显高于对照组的41.5%,差异有统计学意义(P<0.05),两组总有效率比较差异无统计学意义(P>0.05)。心脏彩超结果观察组治疗前后比较,每搏输出量、每分输出量、舒张末期左心房内径、左室短轴缩短百分率均得到改善(P<0.05),射血分数、舒张末期左心室内径改善更明显(P<0.01);与对照组比较,观察组治疗后的射血分数、舒张末期左心室内径(长轴)及舒张末期左心房内径改善更明显,两组比较差异有统计学意义(P<0.05)。结论:米力农小剂量短期维持治疗小儿先天性心脏病并发急性心力衰竭有效、安全。
Objective: To investigate the efficacy and safety of Milrinone in the treatment of congenital heart disease complicated with acute heart failure in children. Methods: Sixty-four children with congenital heart disease complicated with acute heart failure who were treated in our hospital from January 2010 to December 2012 were selected as the observation group, ranging in age from 3 months to 2 years with an average of 8 months. Check the diagnosis of congenital heart disease, in the conventional digitalis concen- tration, furosemide diuretic and captopril vasodilator treatment, to be Milrinone treatment; with no treatment of the same period and only routine treatment of milrinone Of congenital heart disease with acute heart failure in 53 cases as a control group. Observed before and after treatment in children with improved cardiac function and cardiac ultrasound related data changes. Results: The effective rate in observation group was 64.1%, which was significantly higher than that in control group (41.5%), the difference was statistically significant (P <0.05). There was no significant difference in total effective rate between the two groups (P> 0.05). Compared with the control group before and after the treatment, the stroke volume, the output per minute, the left atrial diameter and the fractional shortening of the left ventricle were all improved (P <0.05), the ejection fraction and the end-diastolic diameter of the left ventricle were improved (P <0.01). Compared with the control group, the ejection fraction, end-diastolic left ventricular diameter (long axis) and end diastolic left atrial diameter of the observation group improved more obviously, the difference between the two groups was statistically significant (P < P <0.05). Conclusion: Milrinone low-dose short-term maintenance of children with congenital heart disease complicated with acute heart failure effective and safe.